在第二阶段试验中,圣弗朗西斯科大学和Continuum治疗学科学家开发有前途的MS药物PIPE-307。 UC San Francisco and Continuum Therapeutics scientists develop promising MS drug PIPE-307 in Phase II trials.

旧金山大学和Contineum治疗学大学的科学家在临床试验中研制了一种有前途的药物PIPE-307,以扭转多发性硬化症(MS)的影响。 Scientists at UC San Francisco and Contineum Therapeutics have developed a promising drug, PIPE-307, in clinical trials to reverse the effects of Multiple Sclerosis (MS). 该药物靶向一种受体，该受体促使脑细胞成熟为产生髓鞘的少突胶质细胞，有可能逆转由退行性疾病引起的损伤。 The drug targets a receptor that prompts brain cells to mature into myelin-producing oligodendrocytes, potentially reversing damage caused by the degenerative disease. PIPE-307成功地通过了第一阶段的试验,目前正在进行第二阶段的试验,涉及精神病患者。 PIPE-307 has successfully passed a Phase I trial and is currently in Phase II trials involving MS patients.